
Replimune stock plunges 38% after FDA flags clinical trial issues for skin cancer drug
Replimune Group's stock fell sharply by 38.01% following FDA briefing documents that deemed its skin cancer drug trial data "not interpretable," signaling a major regulatory setback. Other companies like Travelzoo and Amkor Technology also saw signif...


